Biogen CEO: ‘Major bottleneck’ still limits Alzheimer’s drug
By TOM MURPHY AP Health Writer A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market. It was a continuation of a slow debut complicated by coverage questions and doctor concerns. The infused drug has been hailed as a potential breakthrough treatment for a fatal
Continue Reading